Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

Home-Grown Partnership Pays Dividends

Executive Summary

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

You may also be interested in...



Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1

A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.

AZ, Junshi Part Ways Amid China IO Commercial Struggle

Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.

Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs

The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel